4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

4D Molecular Therapeutics (Nasdaq: FDMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in Montreal, Canada, held July 15–18, 2026.

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in Montreal, Canada, held July 15–18, 2026.

The talk will cover 2-year follow-up data from the PRISM Phase 2b trial of investigational intravitreal gene therapy 4D-150 in a broad neovascular AMD population and will be presented on July 18, 2026, at 2:58–3:01 p.m. ET. The presentation will also be available on the 4DMT website.

Argus Jul 1 session

-4.59% close to close Open Argus

Details

News Market Reaction – FDMT

In the Jul 1 session, FDMT declined 4.59%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a 2-year PRISM Phase 2b follow-up podium talk for intravitreal 4D-150 i...

Analysis

This announcement highlights a 2-year PRISM Phase 2b follow-up podium talk for intravitreal 4D-150 in neovascular AMD. Investors may contextualize it alongside recent Phase 3 enrollment progress, while the large $400.0 million shelf remains a key financing watchpoint.

Key Figures

Conference edition: 44th Annual Scientific Meeting Follow-up duration: 2-Year follow up Trial phase: Phase 2b +3 more

Conference edition

44th Annual Scientific Meeting

American Society of Retina Specialists (ASRS) 2026 meeting

Follow-up duration

2-Year follow up

PRISM Phase 2b trial of 4D-150 in neovascular AMD

Trial phase

Phase 2b

PRISM clinical trial evaluating 4D-150

Meeting dates

July 15–18, 2026

ASRS 2026 in Montreal, Canada

Presentation time

2:58–3:01 p.m. ET

ASRS podium presentation on July 18, 2026

Investigational product

4D-150 intravitreal gene therapy

Evaluated in broad neovascular AMD population in PRISM Phase 2b

Historical Context

5 past events · Latest: Jun 29

5 events

1. Jun 29

   Phase 3 enrollment

   24h Move

   +11.0%

   Completed global enrollment early for 4FRONT-2 Phase 3 4D-150 wet AMD trial.

2. Jun 29

   Credit facility

   24h Move

   +11.0%

   Secured up to $200 million non-dilutive credit facility extending cash runway.

3. Jun 12

   Inducement grants

   24h Move

   +4.4%

   Granted 66,900 RSUs to new employees under inducement award plan.

4. May 27

   Investor conferences

   24h Move

   +1.6%

   Announced participation in major June 2026 healthcare investor conferences.

5. May 15

   Inducement grants

   24h Move

   -8.6%

   Issued 141,100 RSUs to new employees, increasing stock-based compensation overhang.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intravitreal gene therapy, neovascular amd, phase 2b, podium presentation

4 terms

intravitreal gene therapy medical

"Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population"

A medical treatment that delivers corrective genetic material directly into the vitreous, the gel-filled space inside the eye, using an injection so cells in the retina can produce a missing or fixed protein. For investors, it matters because successful intravitreal gene therapy can transform chronic eye care from repeated treatments into a potentially long-lasting, one-time or infrequent intervention, creating high upfront development and manufacturing costs, unique regulatory risks, and significant upside if adopted and reimbursed.

neovascular amd medical

"in a Broad Neovascular AMD Population"

Neovascular AMD is an advanced form of age-related macular degeneration where abnormal, leaky blood vessels grow under the central part of the retina, causing rapid and severe loss of central vision; think of it like a leaking pipe damaging the most important part of a camera sensor. It matters to investors because treatments are often ongoing, high-cost medical therapies whose clinical trial results, regulatory approvals and reimbursement decisions can drive large, sustained revenues or sudden swings in a company’s valuation.

phase 2b medical

"PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

podium presentation technical

"today announced a podium presentation at the 44th Annual Scientific Meeting"

A podium presentation is a live, scheduled talk at a professional meeting or conference where a company or researcher formally describes new data, plans or results to an audience. For investors it matters because the presentation is a primary way companies reveal progress and influence market perception—like a product demo that can change confidence and stock value depending on how convincing or newsworthy the information is.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44^th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026.

ASRS 2026 Presentation Details:

Title:	2-Year Follow Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population
Date/Time:	Saturday, July 18, 2026 (2:58 – 3:01 p.m. ET)
Presenter:	Carl Awh, MD, FASRS, Tennessee Retina

The presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications

About 4DMT  

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn. 

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 4D Molecular Therapeutics (Nasdaq: FDMT) announce about the ASRS 2026 meeting?

4D Molecular Therapeutics announced a podium presentation at the 44th American Society of Retina Specialists meeting. According to 4DMT, the talk will feature 2-year follow-up data from the PRISM Phase 2b trial of investigational gene therapy 4D-150 in neovascular AMD.

When is 4D Molecular Therapeutics’ FDMT presentation scheduled at ASRS 2026?

The FDMT presentation is scheduled for Saturday, July 18, 2026, from 2:58–3:01 p.m. ET. According to 4DMT, this brief podium slot will highlight 2-year follow-up results from the PRISM Phase 2b trial evaluating investigational intravitreal gene therapy 4D-150 in neovascular AMD.

What is the topic of 4D Molecular Therapeutics’ PRISM Phase 2b trial presentation on 4D-150?

The presentation covers 2-year follow-up from the PRISM Phase 2b trial of investigational 4D-150. According to 4DMT, 4D-150 is an intravitreal gene therapy being evaluated in a broad neovascular age-related macular degeneration population at the ASRS 2026 scientific meeting.

Who will present 4D Molecular Therapeutics’ 4D-150 PRISM trial data at ASRS 2026?

Carl Awh, MD, FASRS, from Tennessee Retina will present the PRISM Phase 2b data. According to 4DMT, he will deliver the podium talk on 2-year follow-up results for investigational intravitreal gene therapy 4D-150 in neovascular AMD at ASRS 2026.

How can investors access 4D Molecular Therapeutics’ ASRS 2026 presentation on 4D-150?

The ASRS 2026 presentation will also be available on the 4DMT website. According to 4DMT, interested viewers can access it via the pipeline section under posters and publications at https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications following the conference session.